ASX shares that experts rate very positively could be exciting opportunities.
When some businesses have received numerous buy ratings from experts, they are worth a closer look.
Businesses with rapidly growing revenue could be particularly compelling.
Image source: Getty Images
Life360 Inc. (ASX: 360)
Life360 is best known as a tech business that provides an app for families to keep track of each other. It operates in numerous countries, including the US, the UK, ANZ and Canada.
It's currently rated as a buy by 14 analysts, according to Commsec. It's one of the most heavily backed ASX shares right now.
The company is growing strongly – in the second quarter of 2026, it revealed significant growth.
Revenue grew by 38% to $159 million, with monthly active users (MAU) rising 16% to 102.4 million and paying global circles growing by 27% to 3.2 million. US paying circles grew 25% to 2.3 million and international paying circles soared 34% to 0.4 million.
The ASX share has looked to monetise its non-paying circles through advertising. In the three months to June 2026, advertising revenue grew 315% to $22 million.
Life360's profitability metrics are also expanding rapidly. Adjusted operating profit (EBITDA) grew 53% to $20.3 million and positive operating cash flow soared 79% to $23.8 million.
Given that Life360's share price is down more than 60% over the past year (at the time of writing), it could be a very underrated business at this valuation amid worries about AI.
Pro Medicus Ltd (ASX: PME)
Pro Medicus is another ASX share that is strongly backed by analysts.
It is currently rated as a buy by nine analysts, according to Commsec.
Pro Medicus describes itself as a leading healthcare informatics company. It says it provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide.
FY26 was another strong year for the company – revenue grew 22.9% to $261.7 million, underlying operating profit (EBIT) rose 24.4% to $196.1 million, and underlying net profit increased 24.1% to $144.7 million.
However, given how much of the ASX share's revenue now comes from the US, foreign currency plays a sizeable role in the financials. If exchange rates hadn't changed, underlying revenue would have grown 28.4% to $273.5 million, underlying EBIT would have risen 30.6% to $206 million and underlying NPAT would have risen 32.5% to $154.5 million.
Future earnings growth looks very positive, with the company signing 10 new contracts worth a minimum of A$407 million and renewing six (out of six) contracts worth A$141 million at higher transaction rates.
Perhaps most impressively of all, the EBIT margin improved by 90 basis points to 74.9% in FY26.
It's not cheap, but the Pro Medicus share price has dropped around 50% in the past year, making the ASX share much more attractive.
